Docket No.: GNE 3230R1C70

## INFORMATION DISCLOSURE STATEMENT

**Applicant** 

Goddard, et al.

App. No

10/063,597

Filed

.

May 3, 2002

For

SECRETED AND

TRANSMEMBRANE POLYPEPTIDES

AND NUCLEIC ACIDS ENCODING

THE SAME

Examiner

Sandra L. Wegert

Art Unit

1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 6, 2005

(Date)

AnneMarie Kaiser, Reg. No. 37,64

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 38 references to be considered by the Examiner. Also enclosed are 25 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed within three months of the filing date, with an RCE or before receipt of a first office action after an RCE and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Oune 6

AnneMarie Kaiser

Registration No. 37,649

Attorney of Record Customer No. 30,313

(619) 235-8550

1747997\_1 060305

PTO/SB/08 Equivalent

	Application No.	10/063,597
INFORMATION DISCLOSURE	Filing Date	May 3, 2002
STATEMENT BY APPLICANT	First Named Inventor	Goddard, et al.
	Art Unit	1647
(Multiple sheets used when necessary)	Examiner	Sandra L. Wegert
SHEET 1 OF 2	Attorney Docket No.	GNE.3230R1C70

	U.S. PATENT DOCUMENTS				
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	6,025,156	02-15-2000	Gwynn, et al.	
	2	6,124,433	09-26-2000	Falb, et al.	
	3	6,156,500	12-05-2000	Falb, Dean	
	4	6,162,604	12-19-2000	Jacob, Chaim O.	
	5	6,228,582	05-08-2001	Rodier, et al.	
	6	6,395,306	05-28-2002	Cui, et al.	
	7	6,414,117	07-02-2002	Levinson, D. A.	
	8	6,465,185	10-15-2002	Goldfine, et al.	
	9	6,498,235	12-24-2002	Sheppard, et al.	
	10	6,562,343	05-13-2003	Levinson, D. A.	
	11	6,645,499	11-11-2003	Lal, et al.	
	12	6,730,502	05-04-2004	Van Hijum, et al.	
	13	6,737,522	05-18-2004	Sundick, et al.	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	14	ALLMAN, et al. 1996. <i>Blood, Vol 87, No. 12</i> , pp. 5257-5288.	
	15	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell, 3rd Edition</i> , pp. 403-404, 453. New York: Garland Publishing.	
	16	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell 4th Edition</i> , pp. 302, 363-364, 379, 435. New York: Garland Publishing.	
	17	CHEN, et al. 2002. Discordant Protein and mRNA Expression in Lung Adenocarcinomas. Molecular & Cellular Proteomics 1.4, 304-313.	
	18	FU, et al. 1996. Translational regulation of human p53 gene expression. <i>The EMBO Journal, Vol. 15, No. 16</i> , pp. 4392-4401.	
	19	GÖKMEN-POLAR, et al., February 2001, Elevated Protein Kinase C βII Is an Early Promotive Event in Colon Carcinogenesis, <i>Cancer Research, Vol. 61</i> , pp.1375-1381.	
	20	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.	
	21	GYGI, et al. Mar. 1999. Correlation between Protein and mRNA Abundance in Yeast. Molecular and Cellular Biology, 1720-1730.	

Evernines Cianature		Data Osmaldanad	
Examiner Signature		Date Considered	
L			

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

	Application No.	10/063,597
INFORMATION DISCLOSURE	Filing Date	May 3, 2002
STATEMENT BY APPLICANT	First Named Inventor	Goddard, et al.
	Art Unit	1647
(Multiple sheets used when necessary)	Examiner	Sandra L. Wegert
SHEET 2 OF 2	Attorney Docket No.	GNE.3230R1C70

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	τ¹
	22	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .	
	23	HAYNES, et al., 1998. Proteome analysis: Biological assay or data archive? <i>Electrophoresis</i> , <i>Vol. 19</i> , pp. 1862- 1871.	
	24	HU, et al. 2003. Analysis of Genomic and Proteomic Data Using Advanced Literature Mining. Journal of Proteome Research, Vol. 2, pp. 405-412.	·-·
	25	HYMAN et al. Nov. 2002. Impact of DNA Amplification of Gene Expression Patterns. Cancer Research, 62:6240-6245.	
	26	JANG A. Hill RP, Sept. 1997. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. <i>Clin. Exp. Metastasis</i> 15(5): pp. 469-483	·
	27	KONOPKA, et al. June 1986. Variable Expression of the Translocated c-abl Oncogene in Philadelphia-Chromosome-Positive B-Lymphoid Cell Lines from Chronic Myelogenous Leukemia Patients, <i>National Academy of Sciences of the United States of America, Vol. 83, No. 11</i> , pp. 4049-4052	
	28	LEWIN, B. 1994. Oncogenes: Gene Expression and Cancer, Chap. 39, pp.1196-1201. Genes V. New York: Oxford University Press.	_
	29	LEWIN, B. 1997. Regulation of Transcription, Chap. 29, pp. 847-848. <i>Genes VI</i> . New York: Oxford University Press.	
	30	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.	
	31	MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	
	32	OHARA, et al. 2001. Directional cDNA library construction assisted by the in vitro recombination reaction. <i>Nucleic Acids Research, Vol. 29, No e22</i> , pp.1-8.	
	33	ØRNTOFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular &amp; Cellular Proteomics</i> , 1:37-45.	
	34	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.	
	35	POWELL, et al. Oct. 1998. Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. <i>Pharmacogenetics, Vol.5</i> : pp. 411-421.	
	36	SINGLETON, et al. 1992. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. Pathol. Annu, 1(27):165-190.	
	37	VALLEJO, et al. Dec. 2000. Evidence of tissue-specific, post-transcriptional regulation of NRF-2 expression. <i>Biochimie</i> 82(12): 1129-33.	
	38	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World Journal of Surgical Oncology, 2:13.	

1747869\060305

Examiner Signature	Date Considered			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not				

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.